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Background: Self-injury and aggression have been reported in individuals with TSC (tuberous sclerosis com-
plex), yet few data exist about treatment. Everolimus, an mTOR inhibitor, has been FDA-approved for
subependymal giant cell astrocytomas (SEGAs) and renal angiomyolipomas in TSC. However, clinical use of
everolimus with direct, real-time observations of self-injury and aggression in an individual with TSC has
not been reported.
Methods: During an inpatient admission to a neurobehavioral unit, real-time measurements of behaviors and
seizures were recorded. An interdisciplinary team used these data to make treatment decisions and applied
behavioral and pharmacological treatments, one at a time, in order to evaluate their effects.
Results: Aggression and self-injury improved with applied behavioral analysis (ABA), lithium, and asenapine.
Improvements in SEGA size, facial angioﬁbromas, seizures, and the most stable low rates of self-injury were
observed during the interval of treatment with everolimus.
Conclusion:Mechanism-based treatments in the setting of an evidence-based behavioral and psychopharma-
cological intervention program may be a model with utility for characterization and treatment of individuals
with severe behavior and TSC.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Case report
Tuberous sclerosis complex (TSC) is variably expressed based on
the random distribution, number, size, and location of lesions. A
wide variation in the extent and severity of clinical manifestations is
present even between relatives. The phenotype may be mild in some
patients with only minor cutaneous lesions and asymptomatic cardiac
rhabdomyomas or highly disabling in otherswith seizures, intellectualYP3A4, cytochrome p450 3A4;
ymal giant cell astrocytoma;
alian target of rapamycin com-
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Inc.Open access under CC BY-NC-ND lidisability, autism, and self-injurious or aggressive behavior. The source
of this variability and best treatment for those with a severe phenotype
are unknown.
We report the case of a 14-year-old young man with clinically def-
inite tuberous sclerosis complex, epilepsy characterized primarily by
focal motor seizures with altered awareness evolving to bilateral con-
vulsive seizures (left head and eye deviation, drooling, grunting, facial
twitching, and tonic–clonic extremity movements), autism spectrum
disorder, and moderate intellectual disability who was transferred
from a residential treatment facility to an inpatient neurobehavioral
unit because of severe aggression. Aggressive behavior included kick-
ing, biting, head-butting, hair-pulling, hitting, slapping, pushing,
pinching, and scratching. Self-injurious behavior included self-biting
or scratching. Elopement, fecal play, disrobing, and property destruc-
tion were also present.
As an infant, cardiac rhabdomyomas and pathognomonic brain le-
sions were observed. Infantile spasms observed without EEG record-
ing at 6 months evolved into intractable epilepsy without remission
despite multiple medications (phenobarbital, vigabatrin, carbamaze-
pine, topiramate, valproic acid, lamotrigine, and oxcarbazepine) and
2 neurosurgical procedures. Subependymal giant cell astrocytomas, a
shagreen patch, facial angioﬁbromas, a retinal phakoma, and an un-
gual ﬁbroma also developed over time.cense.
Fig. 1.Magnetic resonance imaging of subependymal giant cell astrocytoma (SEGA) be-
fore and after treatment with everolimus. Pretreatment (A) axial and (B) coronal and
(C) axial and (D) coronal 3D-T1-postcontrast-weighted images after 5-month treat-
ment with everolimus show a mild reduction in size of the SEGA.
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concern. Despite behavioral treatment andmultiplemedications—meth-
ylphenidate, dextroamphetamine, sertraline, aripiprazole quetiapine,
alprazolam, amitriptyline, clonidine, guanfacine, risperidone, paroxetine,
and diazepam, severe aggression resulted in residential placement. After
four years in residential treatment, the severity of aggression prompted a
referral to a neurobehavioral unit where inpatient evaluation and treat-
ment were recommended.
Real-time recording of behaviors and seizures as well as a struc-
tured daily routine including activities of daily living, academic tasks,
and scheduled leisure time was implemented upon admission. Obser-
vations revealed aggression and self-injury that occurred throughout
the day at an average rate of 68.0 per hour and 4.0 per hour, respec-
tively. Aggression was likely to occur in bursts and last for long dura-
tions, whereas self-injury occurred as discrete instances or in short
episodes. An extensive functional behavioral analysis was initiated
immediately upon admission to determine what environmental vari-
ables were maintaining these behaviors. This process involves isolat-
ing possible motivational factors hypothesized to trigger the target
behavior and manipulating responses during brief and repeated ex-
perimental sessions. The highest rates of aggressive behavior were ob-
served during transitions and instructional demands or when adult
attention was unavailable. Collective results identiﬁed the following
functions: to escape from transitions, academic tasks, and daily living
tasks and to gain access to adult attention. Self-injury was not reliably
observed during the functional analysis; thus, conclusions about its
function could not be made. Following the assessment period, the be-
havioral psychology team initiated evaluations of possible function-
based behavioral interventions.
During the functional analysis process, medical attention focused
primarily on management of epilepsy. Admission medications includ-
ed oxcarbazepine, tranxene (a benzodiazepine derivative), vigabatrin,
and melatonin. Oxcarbazepine and vigabatrin were continued, and
abortive treatment (rectal diazepam or nasal midazolam) was added
for single seizures lasting longer than 5 min or a cluster of three or
more seizures lasting at least 30 s in a 24-hour period. These seizures
requiring diazepam or midazolam either due to duration or total
number in 24 h were classiﬁed as “severe seizures” and documented
separately. The percentage of severe seizures during baseline was
23.8% (5/21) while taking vigabatrin and oxcarbazepine over 8 weeks.
Ictal activity was suspected near the SEGA in the right frontal lobe;
therefore, everolimus treatment was initiated to reduce the size of
the SEGA. A conﬁrmatory EEG was not feasible because of the severity
of behaviors. Dose titration and serum level monitoring were con-
ducted in accordance with FDA-approved guidelines [1,2]. Overall,
data recorded during therapeutic serum levels of everolimus revealed
a slight decrease in size of the SEGA (Fig. 1), decreased frequency of
severe seizures, and improvement in facial angioﬁbromas. Severe
seizures decreased to 8% (3/39) during 12 weeks of everolimus at ther-
apeutic serum levels (5–15 ng/ml) and oxcarbazepine. After discon-
tinuation of everolimus due to parental concern regarding an adverse
event (pneumonia), frequency of severe seizures increased to 21%
(6/29) over 8 weeks with oxcarbazepine alone. Other antiepileptic
medication changes included weaning of vigabatrin and addition of
ruﬁnamide. These changes did not affect seizures, and ruﬁnamide was
discontinued after 2 weeks because of increased aggression and agitation.
Lithium was initiated to target aggression, while the behavioral
psychology team evaluated possible behavioral interventions. After
initiation of lithium, an initial behavioral intervention was imple-
mented 24 h daily. This intervention, behavioral extinction, was
based on the ﬁnding of the functional analysis that aggressive behav-
ior was maintained, in part, by access to attention. Behavioral extinc-
tion is a process that involves no longer providing reinforcement
for target behaviors. Therefore, during this period, staff no longer pro-
vided statements of concern (e.g., “Stop doing that, it hurts.”) when
aggressive behaviors were observed. In combination with extinction,a continued increase in lithium toward a therapeutic dose resulted
in a steady decrease in aggressive behavior, achieving a 69% reduction
relative to baseline. After approximately onemonth, additional behav-
ioral intervention components were added to extinction and imple-
mented 24 h daily based on data from intensive behavioral therapy
sessions. These evidence-based behavioral treatments consisted of a
structured schedule, functional communication, noncontingent rein-
forcement, differential reinforcement, and redirection. A structured
schedule was used to enhance the predictability for required work,
transitions, or down time. Functional communication involved teach-
ing appropriate communication using a picture card to request a break
from a transition or a task or for attention from adults. Noncontingent
reinforcement involved providing free access to highly preferred
leisure items that were also found to be associated with low levels of
aggressive and self-injurious behavior during transitions and down
time. Differential reinforcement involved providing preferred snacks
and attention during compliance with a transition or task demand
without engaging in problem behavior. Finally, redirection involved
physicallymoving away from the target of aggression using a speciﬁed
procedure.
Shortly after the initiation of full behavioral treatment, everolimus
reached goal levels (5–15 ng/ml). Asenapine 5 mg twice daily was
added to target residual aggression and further mood stabilization.
Asenapine was chosen after past failed trials of multiple ﬁrst- and
second-generation antipsychotics over the course of several years.
During this period of intensive behavioral therapy and medication
management with lithium, asenapine, everolimus, and oxcarbazepine,
aggressive and self-injurious behaviors were observed to be at the
lowest and steadiest levels of the admission, achieving an 80% and
78% reduction from baseline, respectively. Low rates of aggressive
behavior maintained after everolimus was discontinued and slight
modiﬁcations were made to the behavioral treatment, with a 92%
reduction relative to baseline. Rates of self-injury remained low but
became more variable about one month after everolimus was dis-
continued, with a 65% reduction in self-injury relative to baseline dur-
ing the last few weeks of the admission.
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Fig. 2. Schematic diagram of the mammalian target of rapamycin (mTOR) pathway and site of action of mechanism-based treatments.
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Aggression, self-injury, seizures, and SEGA sizewere targets of treat-
ment in this case. Aggressionwas decreased by behavioral intervention,
lithium, and asenapine. Severe seizures were the lowest when treated
with everolimus and oxcarbazepine, and the frequency increased to
baseline levels when everolimus was discontinued. Everolimus and
lithium, two of the treatments used in this case, are both directly in-
volved in the underlying neurobiology of TSC. Everolimus directly in-
hibits abnormally elevated mTOR activity associated with mTORC1,
and lithium inhibits inositol-1-phosphate, which would typically in-
crease activity of mTORC2 (Fig. 2). Everolimus has been FDA-approved
for treatment of SEGAs and renal angiomyolipomas (AMLs) in TSC;
however, the effects of everolimus on behavior and seizures have not
been systematically studied. In contrast, the efﬁcacious usage of lithium
in aggressive behavioral disorders has been reported for decades. Early
studies of lithium's utility in manic–depressive illness concomitantly
showed signiﬁcant reduction of aggression in animal models [3], and
the beneﬁt of lithium in youth with severe aggression and intellectual
disability quickly appeared in the literature [4,5]. Similarly, behavioral
interventions have a large body of literature supporting their effective-
ness in reducing problem behavior in individuals with autism spectrum
disorders and intellectual disabilities [6].
Asenapine is a new second-generation antipsychotic indicated for
the treatment of schizophrenia in the US and of mania associatedwith bipolar affective illness in both the US and Europe. Its sublingual
formulation is unique among antipsychotics [7–10]. There is no cur-
rent literature regarding the usage of asenapine in youth or in any pa-
tients with autism or other intellectual disabilities.
Aggression and self-injury have been reported in TSC; however,
behavioral functions and response to treatment are rarely reported
[11,12]. Previous case reports have described intellectual disability
and seizures associated with self-injury in one clinical population of
individuals with TSC. Frontal lobe ictal activity, the same location as
the SEGA in this case, was also an association [13]. An integrated, in-
terdisciplinary, evidence-based model was used for clinical care in
this adolescent with TSC, SEGAs, epilepsy, cognitive limitations, severe
aggression, and self-injury [14,15]. Multicenter studies are warranted
to evaluate the utility and generalizability of this model for similarly
affected individuals.
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